CG-SLD did not reduce lymphedema incidence compared with SC at 24 months. Although early reductions in lymphedema incidence and severity were observed for CG-SLD, these were not maintained beyond 6 months when interventions ceased. The study was underpowered, and larger trials are required to determine whether early prophylactic strategies provide durable benefit.
Building similarity graph...
Analyzing shared references across papers
Loading...
Melody C. Brown
T. S. Lee
Isabel Li
Annals of Surgical Oncology
The University of Sydney
Royal North Shore Hospital
National Health and Medical Research Council
Building similarity graph...
Analyzing shared references across papers
Loading...
Brown et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69df2c50e4eeef8a2a6b1473 — DOI: https://doi.org/10.1245/s10434-026-19559-4